多发性硬化合并三叉神经痛微血管减压术长期结局的系统综述与荟萃分析
该系统综述与荟萃分析纳入30项研究、429例多发性硬化合并三叉神经痛(TN-MS)接受微血管减压术(MVD)的患者,汇总长期无痛(BNI I级)成功率为30.2%(95%CI 24.2%-36.9%),最常见并发症为一过性面部麻木。结论认为MVD在TN-MS中疗效低于经典TN,但不应被绝对排除。
要点
- TN-MS患者MVD长期无痛(BNI I级)汇总成功率仅30.2%。
- 96.6%的TN-MS患者术中发现神经血管压迫。
- 术后最常见并发症为一过性面部麻木。
核心结论
- MVD在TN-MS患者中的疗效低于经典TN患者,长期无痛成功率约30%。
- 但MVD仍可能带来有意义的疼痛缓解,尤其对存在神经血管压迫的患者。
- MVD不应被绝对排除作为TN-MS的治疗选择。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase、Scopus和Web of Science数据库(2024年6月),遵循PRISMA指南。
- 从523条唯一记录中纳入30项研究,共429例TN-MS接受MVD患者,其中265例为独立患者。
- 采用随机效应模型进行比例荟萃分析,使用MINORS工具评估偏倚风险。
主要发现
- 96.6%的患者术中发现神经血管压迫。
- MVD达到BNI I级的汇总成功率为30.2%(95%CI 24.2%-36.9%)。
- 各分析间异质性低(I2=0%-25%)。
- 术后最常见并发症为一过性面部麻木。
- 纳入研究发表偏倚不显著。
关键数值与推荐
- 主要结局为末次随访时长期无痛状态,定义为BNI评分I级。
- MVD成功定义为达到BNI评分I级,汇总成功率为30.2%(95%CI 24.2%-36.9%)。
临床怎么用
- 对TN-MS患者,MVD可作为个体化治疗选项,尤其存在神经血管压迫时。
- 术前应与患者充分沟通约30%的长期无痛成功率及一过性面部麻木风险。
- 不应将TN-MS视为MVD的绝对禁忌证。
局限性
- 纳入研究均为非随机研究,证据等级受限。
- 需要进一步前瞻性研究来细化患者选择和优化结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Trigeminal neuralgia (TN) is a debilitating condition often associated with multiple sclerosis (MS), in which the presence of demyelinating plaques in the pons can impact the trigeminal nerve. Microvascular decompression (MVD) is the gold-standard surgical treatment for classic TN but is traditionally contraindicated in TN-MS patients due to limited efficacy and concerns over neurovascular compression as the sole etiology. This systematic review aimed to evaluate the outcomes of MVD in TN-MS patients, focusing on pain relief and complications. METHODS: A systematic search of the PubMed, Embase, Scopus, and Web of Science databases was conducted in June 2024, adhering to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Studies reporting on MVD outcomes in TN-MS patients were included. Data on demographics, clinical characteristics, surgical outcomes, and complications were extracted. The primary outcome was long-term pain-free status (Barrow Neurological Institute [BNI] score of I) at the final follow-up. A meta-analysis of proportions was performed using a random-effects model. Risk of bias was assessed using the Methodological Index for Non-Randomized Studies tool. RESULTS: From 523 unique records, 30 studies were included, consisting of 429 TN-MS patients treated with MVD, with 265 unique patients. Neurovascular compression was identified in 96.6% of the patients. The pooled success rate of MVD, defined as achieving a BNI score of I, was 30.2% (95% CI 24.2%-36.9%). Heterogeneity was low (I2 = 0%-25%) across analyses. The most common complication reported after MVD was transient facial numbness. Publication bias was not significant in the included studies. CONCLUSIONS: MVD is less effective in TN-MS patients than in those with classic TN, with approximately 30% achieving long-term pain-free outcomes. However, MVD may still offer meaningful relief, particularly in patients with neurovascular compression. Given these findings, MVD should not be categorically excluded as a treatment option for TN-MS. Further prospective studies are needed to refine patient selection and optimize outcomes.
引用
- Sultan H, Sabahi M, Gholamshahi H, et al. Long-term outcomes of microvascular decompression for trigeminal neuralgia in multiple sclerosis: a systematic review and meta-analysis. J Neurosurg. 2025. PMID: 41349020. doi:10.3171/2025.7.JNS243258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。